Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.

Oncotarget - 1 Jan 2015

Bishop Jennifer L, Sio Alexander, Angeles Arkhjamil, Roberts Morgan E, Azad Arun A, Chi Kim N, Zoubeidi Amina

Abstract excerpt

Efficacy of Enzalutamide (ENZ) in castration resistant prostate cancer (CRPC) patients is short-lived. Immunotherapy like T cell checkpoint blockade may improve patient survival. However, when and where checkpoint molecules are expressed in CRPC and whether immune evasion is a mechanism of ENZ resistance remains unclear. Thus, we investigated whether clinically relevant immunotherapy targets, specifically PD-L1/2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Receptors, Androgen
Share to B7-H1 Antigen
Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dendritic Cells

Share to Immunotherapy

Share to Leukocytes, Mononuclear

Share to Neoplasm Transplantation

Share to Nitriles

Source

Open in PubMed Open full text

Identifiers

PMID: 25428917
DOI: 10.18632/oncotarget.2703
PMCID: PMC4381591

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.PMID 25428917Read ↗

A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.Semantic proximity Read ↗

A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor GenesSemantic proximity Read ↗

Longitudinal Immune Profiling Reveals Unique Myeloid and T-cell Phenotypes Associated with Spontaneous Immunoediting in a Prostate Tumor Model.Semantic proximity Read ↗

Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade RespondersSemantic proximity Read ↗

Flightless I Homolog Reverses Neo-Endocrine Therapy Resistance through YBX1/PD-L1 Axis Mediated-Immune Evasion in Prostate CancerSemantic proximity Read ↗

Targeting the TLK1-Nek1-Mediated Activation of YAP1 Attenuates PD-L1 and Inflammation Set for Prostate Cancer ImmunoevasionSemantic proximity Read ↗

Cell-resolved high-dimensional imaging analysis, therapeutic modeling, and a Phase Ib clinical study establish BCL-2 as a target across heterogeneous CRPC subtypesSemantic proximity Read ↗

A Glutamine antagonist-modulated tumor microenvironment unleashes enzalutamide’s immunotherapeutic effectsSemantic proximity Read ↗

Castration-mediated IL-8 Promotes Myeloid Infiltration and Prostate Cancer ProgressionSemantic proximity Read ↗

Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).Semantic proximity Read ↗

Targeting the TLK1-Nek1-Mediated Activation of YAP1 Attenuates PD-L1 and Anti-Inflammation Set for Prostate Cancer ImmunoevasionSemantic proximity Read ↗

MYC and p53 alterations cooperate through VEGF signaling to repress cytotoxic T cell and immunotherapy responses in prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.